Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isotonix OPC-3 is a dietary supplement and nutraceutical formulated as an isotonic-capable powder containing a synergistic blend of plant-derived antioxidants, specifically oligomeric proanthocyanidins (OPCs). Developed by Market America, the product features a combination of grape seed extract, red wine extract, bilberry extract, citrus bioflavonoids, and Pycnogenol (a patented extract from French maritime pine bark). It utilizes an isotonic delivery system—a powder that, when mixed with a specific amount of water, creates a solution with the same osmotic pressure as bodily fluids like tears and blood. This formulation is designed to facilitate rapid absorption and high bioavailability of the active flavonoids. The supplement is primarily used to support cardiovascular health by neutralizing reactive oxygen species, reducing inflammation, and improving endothelial function and blood flow.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isotonix OPC-3.